News|Articles|February 13, 2025
Executive Summary: Addressing Regulatory Requirements for CRISPR sgRNA Purity with Orthogonal Chromatography
Author(s)Agilent
The increasing demand for high-purity, regulatory-compliant guide RNA (gRNA) manufacturing in the CRISPR gene editing market underscores the need for advanced production capabilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5